Open AccessOptimal Treatment Regimens for 5′‐Deoxy‐5‐fluorouridine, with or without ( E )‐5‐(2‐Bromovinyl)‐2′‐deoxyuridine, against Various Tumors in Mice
Author(s) -
Iigo Masaaki,
Miwa Masanori,
Clercq Erik
Publication year - 1990
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1990.tb02586.x
Subject(s) - lewis lung carcinoma , floxuridine , prodrug , deoxyuridine , pharmacology , fluorouracil , chemistry , chemotherapy , medicine , cancer , biochemistry , metastasis , dna
The antitumor activity of 5′‐deoxy‐5‐fluorouridine (DFUR), a prodrug of 5‐fluorouracil (5‐FU), is markedly enhanced if DFUR treatment is combined with ( E )‐5‐(2‐bromovinyl)‐2′‐deoxyuridine (BVDU). Combined oral administration of DFUR (10 mg/kg) and BVDU (10 mg/kg) three times (every 3 h) per day for 5 days afforded greater antitumor activity than a single dose of DFUR (300 mg/kg/day) for 5 days in mice bearing either adenocarcinoma 755 or Lewis lung carcinoma, while in the colon 26 system the antitumor effects of both treatment regimens were equivalent. Thus, a low‐dose regimen of DFUR when combined with BVDU provides a similar or greater antitumor activity than a high‐dose regimen of DFUR that is not combined with BVDU. The area under the curve of plasma 5‐FU following a treatment with the combination of DFUR (10 mg/kg) and BVDU (10 mg/kg) was equal to that following DFUR (300 mg/kg) treatment.